Novartis Reports Strong H1 2025 Performance with $22 Billion Revenue from China and $825 Million from Pluvicto

Jul 17, 2025 14:20 CST Updated 14:20

Novartis

Drug Development and Manufacturing

On July 17, Novartis released its 2025 H1 financial report,Net sales in the first half of the year were US$27.287 billion, an increase of 12% year-on-year,Net profit was US$7.633 billion, an increase of 29% year-on-year. Net sales in the second quarter were US$14.054 billion（+12%）, with a net profit of 4.024 billion US dollars（+24%）。

H1 2023 Revenue in China Reached $2.2 Billion, Up 8% Year-on-Year

Source: Novartis 2025 H1 Financial Report, same as below

NovartisFocus onCardiovascular, Renal and Metabolic Diseases, Immunology, Neuroscience, and OncologyThe four core therapeutic areas generated revenues of $5.173 billion, $4.958 billion, $2.759 billion, and $8.199 billion respectively in the first half of the year.

The growth in the second quarter was mainly due toKisqali(Ribociclib),Entresto(Sacubitril Valsartan),Kesimpta(Ofatumumab),Scemblix(Asciminib),Leqvio(Inclisiran) andPluvicto Products continue to perform strongly.

In the first half of 25 years, Novartis was the most popularSales Drug isEntresto、Cosentyx andKisqali achieved sales of $4.618 billion (+22%), $3.163 billion (+11%), and $2.133 billion (+59%), respectively. According to this growth trend,Entresto is expected to join the billion-dollar club this year.

Star Nuclear MedicinePluvicto's Sales in the First Half of the Year Reached $825 Million(+26%), this product has maintained rapid growth since its launch in 2022, breaking through the 1 billion US dollars mark for the first time in 2024. Another nuclear medicine, Lutathera, generated 400 million US dollars in revenue in the first half of the year, increasing by 16% year-on-year.

The second half of 2025,NovartisEptinezumab andAsciminib is expected to gain a new indication in China.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only, and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn